Cross-industry partnership reduces the cost of popular diabetes, asthma and other brand name drugs
Inside Rx, a new initiative from Express Scripts, partners with GoodRx, drug manufacturers and drug stores to save Americans an average of 34% at 40,000 pharmacies
Express Scripts has launched Inside Rx, a new, partially owned subsidiary that applies Express Scripts' purchasing power to expand affordable access to brand and generic medications for patients in need. Inside Rx has partnered with GoodRx, America's leading source for prescription drug prices and savings, to deliver average savings of 34% on prescription medications for the uninsured and those who experience high out-of-pocket costs for their prescription medications.
Patients can visit www.goodrx.com/brand or download the GoodRx mobile app to instantly access significant savings for more than 40 popular brand name drugs that treat diabetes, asthma, heart disease, depression, gastrointestinal disorders, gout, and other common illnesses. While savings vary per drug and pharmacy, eligible patients can save an average of 34% off of the drug's typical cash price, which could translate into savings of hundreds or even thousands of dollars per person per year.
Benefiting from these discounts is easy; eligible patients simply present the discount via card or mobile app at one of 40,000 pharmacies nationwide, including CVS, the Kroger Family of Pharmacies and Walgreens. There are no membership fees or costs to obtain savings. A complete list of available medications and participating pharmacies are available at www.insiderx.com.
"We have a unique opportunity to put medicine within reach of those who need it. By practicing pharmacy smarter, we are bringing together companies across healthcare to truly deliver value," said Express Scripts President and CEO Tim Wentworth. "We are proud to power a novel solution that makes brand-name medicines more affordable and accessible, particularly for people without prescription coverage."
The program represents an important, and unique, cross-industry collaboration among Inside Rx, GoodRx, participating retail pharmacies, and major pharmaceutical companies, including Boehringer Ingelheim, Eli Lilly and Company, Lundbeck, Novo Nordisk, Sanofi, Takeda Pharmaceuticals and Teva Pharmaceuticals. All stakeholders share a focus to ensure patients have expanded access to affordable medications. Today, more than 30 million Americans pay the full cost of their prescriptions.
"The GoodRx / Inside Rx program is a simple and effective way to help millions of Americans who struggle to afford their prescriptions," said Doug Hirsch, co-founder and co-CEO of GoodRx. "GoodRx is proud to partner with Inside Rx to reduce the cost of diabetes, asthma and other important drugs that patients need."
"We are pleased to participate in Express Scripts' new program that will play an important role in helping under-insured and uninsured patients receive the medicines they need at a price they can afford," said Brad Fluegel, Senior Vice President, Chief Healthcare Commercial Market Development Officer, Walgreens.
"Kroger is excited to partner with Express Scripts on this new program that creates affordability and expands access to medications for many of our patients," said Colleen Lindholz, President of Pharmacy and The Little Clinic, The Kroger Co. Soon, Inside Rx cards also will be available at the Kroger Family of Pharmacy locations.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.